Celera formally separates from Applied Biosystems' owner for Invitrogen's $7b buy

RNA microarray chip technology developed by the University of Queensland licensed to Invitrogen.

Biologic classification to fast-track VitroGro development.

HuMEC Medium is a serum-free formulation with frozen supplements containing growth factors and other components.

The iBlot Dry Blotting System efficiently and reliably transfers proteins from polyacrylamide gels in seven minutes or less.

The Novex Sharp Protein Standard provides bands in a pre-stained format for various protein gel electrophoresis applications.

PharmAust's (ASX:PAA) wholly owned subsidiary Mimotopes has signed a three-year contract with California-based Invitrogen to exclusively supply research-grade peptides to the global biotech group's customer base.

Brisbane based Bio-Layer, a wholly-owned subsidiary of SSH Medical (ASX:SSH), has entered into a development and marketing agreement with a US-based life sciences company for the use of its surface coating product Mix&Go.

PharmAust (ASX:PAA) subsidiary Mimotopes will team up with US-based Genzyme Pharmaceuticals in a strategic alliance to provide peptide products and services to both companies' customers globally.

SSH Medical (ASX:SSH) re-listed today on the ASX following a capital raising of AUD$4.26 million and the acquisition of unlisted Brisbane-based materials sciences specialist Bio-Layer.

PharmAust (ASX:PAA) has appointed Dr Paul D'Sylva as managing director, also making him responsible for the company's wholly owned subsidiary companies Epichem, Mimotopes and PharmAust Manufacturing.